Euroscreen has announced that it has completed its five-year target discovery and screening collaboration with Cephalon. In the final two year phase of the collaboration, Euroscreen delivered optimised lead molecules on a non-disclosed, specific GPCR target, triggering a milestone payment by Cephalon. Financial details were not disclosed.